Abstract
Stevia rebaudiana Bertoni is a sweet and nutrient-rich plant belonging to the Asteraceae family. Stevia leaves contain steviol glycosides including stevioside, rebaudioside (A to F), steviolbioside, and isosteviol, which are responsible for the plant’s sweet taste, and have commercial value all over the world as a sugar substitute in foods, beverages and medicines. Among the various steviol glycosides, stevioside, rebaudioside A and rebaudioside C are the major metabolites and these compounds are on average 250-300 times sweeter than sucrose. Steviol is the final product of Stevia metabolism. The metabolized components essentially leave the body and there is no accumulation. Beyond their value as sweeteners, Stevia and its glycosdies possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity and tooth decay. Studies have shown that steviol glycosides found in Stevia are not teratogenic, mutagenic or carcinogenic and cause no acute and subacute toxicity. The present review provides a summary on the biological and pharmacological properties of steviol glycosides that might be relevant for the treatment of human diseases.
Keywords: Stevia, steviol glycosides, stevioside, rebaudiosides A, cancer, diabetes, toxicity.
Current Pharmaceutical Design
Title:A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana
Volume: 23 Issue: 11
Author(s): Amir Abbas Momtazi-Borojeni, Seyed-Alireza Esmaeili, Elham Abdollahi and Amirhossein Sahebkar*
Affiliation:
- Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad 9177948564,Iran
Keywords: Stevia, steviol glycosides, stevioside, rebaudiosides A, cancer, diabetes, toxicity.
Abstract: Stevia rebaudiana Bertoni is a sweet and nutrient-rich plant belonging to the Asteraceae family. Stevia leaves contain steviol glycosides including stevioside, rebaudioside (A to F), steviolbioside, and isosteviol, which are responsible for the plant’s sweet taste, and have commercial value all over the world as a sugar substitute in foods, beverages and medicines. Among the various steviol glycosides, stevioside, rebaudioside A and rebaudioside C are the major metabolites and these compounds are on average 250-300 times sweeter than sucrose. Steviol is the final product of Stevia metabolism. The metabolized components essentially leave the body and there is no accumulation. Beyond their value as sweeteners, Stevia and its glycosdies possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity and tooth decay. Studies have shown that steviol glycosides found in Stevia are not teratogenic, mutagenic or carcinogenic and cause no acute and subacute toxicity. The present review provides a summary on the biological and pharmacological properties of steviol glycosides that might be relevant for the treatment of human diseases.
Export Options
About this article
Cite this article as:
Momtazi-Borojeni Abbas Amir, Esmaeili Seyed-Alireza, Abdollahi Elham and Sahebkar Amirhossein*, A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612822666161021142835
DOI https://dx.doi.org/10.2174/1381612822666161021142835 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Investigation on the Antidiabetic Effect of 3-aryl-1-(5-methylisoxazol-3-ylamino)-1-(4-nitrophenyl) Propan-1-one
Letters in Drug Design & Discovery Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Current Pharmaceutical Design Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology Platelet Function Testing in Atherothrombotic Disease
Current Pharmaceutical Design Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
Current Drug Discovery Technologies Stages of HIV Replication and Targets for Therapeutic Intervention
Current Topics in Medicinal Chemistry The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry Editorial
Current Diabetes Reviews Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets By Passing Microbial Resistance: Xylitol Controls Microorganisms Growth by Means of Its Anti-Adherence Property
Current Pharmaceutical Biotechnology Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific Receptors
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets